Skip to main content
Jens Lohr, MD, Oncology, Boston, MA

JensGLohrMD

Oncology Boston, MA

Clinical Fellow in Medicine, Dana-Farber Cancer Institute

Are you Dr. Lohr?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 36 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    44 Binney St
    Medical Oncology, Dfci, Smith 353
    Boston, MA 02115
    Phone+1 617-632-3485

Summary

  • Dr. Jens Lohr, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, Utah, and California. He is affiliated with Dana-Farber Cancer Institute and Brigham and Women's Hospital.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2012
  • University of California (San Francisco)
    University of California (San Francisco)Residency, Internal Medicine, 2006 - 2008
  • Ruprecht Karl University Faculty of Medicine
    Ruprecht Karl University Faculty of MedicineClass of 1997

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2009 - 2026
  • UT State Medical License
    UT State Medical License 2024 - 2026
  • MA State Medical License
    MA State Medical License 2010 - 2025
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Press Mentions

  • American Thyroid Association Awards ThyCa Research Grant to Jens Lohr, MD, PhD, Dana Farber Cancer Institute
    American Thyroid Association Awards ThyCa Research Grant to Jens Lohr, MD, PhD, Dana Farber Cancer InstituteAugust 9th, 2017